Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
2(50.0%)
Phase 1
2(50.0%)
4Total
Phase 2(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05066672Phase 2Completed

Phase 2 Study of NV-5138 in Adults With Treatment Resistant Depression

Role: lead

NCT06235905Phase 2Completed

Open-Label of SPN-820 in Adults With Major Depressive Disorder

Role: lead

NCT05152680Phase 1Completed

Mass Balance Study of NV-5138 in Healthy Male Subjects.

Role: lead

NCT03606395Phase 1Completed

Safety, Tolerability, PK and Efficacy of Single Doses of NV-5138 in Healthy Volunteers and Subjects With Treatment-Resistant Depression

Role: lead

All 4 trials loaded